Meredith A Morgan

 Meredith A. Morgan
Theodore S Lawrence M.D., Ph.D. and Patricia Krause Research Professor of Radiation Oncology
Associate Chair, Department of Radiation and Cancer Biology
Department of Radiation Oncology and Professor of Radiation Oncology
Medical School
University of Michigan Medical School
Radiation Oncology
1301 Catherine Street
Ann Arbor, Michigan 48109 SPC 5637
[email protected]
Available to mentor
Meredith A Morgan
Meredith A. Morgan
Professor
  • About
  • Qualifications
  • Center Memberships
  • Research Overview
  • Recent Publications

  • Manage Your Profile

    • About

    Dr. Morgan leads a laboratory focused on improving standard radiation and chemoradiation therapies through the use of novel agents targeting DNA damage response and repair. Her research program prioritizes pre-clinical research with strong clinical/translational relevance with an emphasis on pancreatic cancer. More specific areas of research interest include DNA double-strand break repair, DNA replication, cell cycle and biomarker development.

    Qualifications
    • Research Fellow
      University of Michigan, United States
      2002 - 2005
    • Postdoctoral Research Fellow
      West Virginia University, United States
      2002 - 2002

    Center Memberships
    • Center Member
      Rogel Cancer Center

    Research Overview

    DNA damage response inhibitors
    Radio - and chemo- sensitization
    DNA repair and DNA replication stress
    Immunotherapy and tumor immunology
    Translational research
    Pancreatic cancer and diffuse intrinsic pontine glioma

    Recent Publications

     See All Publications
    • Journal Article
      H3K27M enhances basal ATM signaling but is not required for radiosensitization of diffuse midline glioma via ATM inhibition with AZD1390.
      Peterson ER, Parsels LA, Li Z, Zhao X, Hess LD, Guo Y, Messinger D, Parsels JD, Wang Z, Qin T, Valvo VM, Franson AT, Castro MG, Yadav VN, Lawrence TS, Koschmann C, Zhang Q, Wahl DR, Morgan MA. Mol Cancer Ther, 2026 Jul 14; DOI:10.1158/1535-7163.MCT-24-1019
      PMID: 42444560
    • Journal Article
      Liver Metastases License Neutrophils through IL1 to Potentiate Cancer Progression
      Pearson AN, Waninger J, Huber AK, Holcomb EA, James JG, Kyi J, Elaimy AL, Wang Z, Lasse-Opsahl EL, SenGupta S, Elliott DA, Choi E, Zhang Q, Morgan MA, Chang DT, Lawrence TS, Courtney A, Shah YM, Knight JS, Di Magliano MP, Yoo S, Crivelli S, Parent CA, Ramnath N, Bryant AK, Zou W, Green MD. Cancer Immunology Research, 2025 Dec 1; 13 (12): 2023 - 2036. DOI:10.1158/2326-6066.CIR-24-1074
      PMID: 40906822
    • Journal Article
      DMG-02. Targeting B7-H3 in combination with radiation against diffuse midline glioma
      Li Z, Guo Y, Wang Z, Parsels L, Parsels J, Wahl D, Lawrence T, Venneti S, Koschmann C, St. Croix B, Morgan M, Zhang Q. Neuro-Oncology Pediatrics, 2026 Mar 14; 1 (Supplement_1): DOI:10.1093/neuped/wuaf001.033
    • Journal Article
      HGG-03. ATRX loss drives epigenetic dysregulation of p16 in pediatric high-grade glioma
      Messinger D, Patel J, Doherty R, Kuchinski K, Clausen M, Momen F, Schwark K, de la Nava Martin D, Parsels LA, Parsels JD, Ji S, Mota M, Venneti S, Zhang Q, Morgan M, Qin T, Yadav VN, Koschmann C. Neuro-Oncology Pediatrics, 2026 Mar 14; 1 (Supplement_1): DOI:10.1093/neuped/wuaf001.139
    • Journal Article
      A New Tool to Decrease Interobserver Variability in Biomarker Annotation in Solid Tumor Tissue for Spatial Transcriptomic Analysis
      Palavalasa S, Baker E, Freeman J, Gokul A, Zhou W, Thomas D, Al-Holou WN, Morgan MA, Lawrence TS, Wahl DR. Current Issues in Molecular Biology, 2025 Jul 29; 47 (7): 531 - 531. DOI:10.3390/cimb47070531
    • Preprint
      A New Tool to Decrease Interobserver Variability in Biomarker Annotation in Solid Tumor Tissue for Spatial Transcriptomic Analysis
      Palavalasa S, Baker E, Freeman J, Gokul A, Zhou W, Thomas D, Al-Holou W, Morgan M, Lawrence T, Wahl D. 2025 Jun 19; Preprints.org, DOI:10.20944/preprints202506.1311.v1
    • Journal Article
      Olaparib and Radiotherapy Induce Type I Interferon- and CD8+ T Cell-Dependent Sensitization to Immunotherapy in Pancreatic Cancer.
      Valvo VM, Zhang Q, Jiang L, Holcomb EA, Pearson AN, Edmunds AG, Faulkner HG, James JG, Tate A, Huber AK, Wang Z, Guo Y, Karnak D, Parsels LA, Parsels JD, Lei YL, Rehemtulla A, Lin H, Carpenter ES, Wahl DR, Sahai V, Lawrence TS, Green MD, Morgan MA. Mol Cancer Ther, 2025 Mar 10; OF1 - OF16. DOI:10.1158/1535-7163.MCT-24-0210
    • Journal Article
      SLC4A11 mediates ammonia import and promotes cancer stemness in hepatocellular carcinoma
      Elaimy AL, El-Derany MO, James J, Wang Z, Pearson AN, Holcomb EA, Huber AK, Gijón M, Bell HN, Sanghvi VR, Frankel TL, Su GL, Tapper EB, Tai AW, Ramnath N, Centonze CP, Dobrosotskaya I, Moeller JA, Bryant AK, Elliott DA, Choi E, Evans JR, Cuneo KC, Fitzgerald TJ, Wahl DR, Morgan MA, Chang DT, Wicha MS, Lawrence TS, Shah YM, Green MD. Jci Insight, 2025 Oct 10; 9 (21): DOI:10.1172/jci.insight.184826

    Featured News & Stories

         An image of a Linear Accelerator (LINAC)
    Illuminate

    Refining Radiation

    In 2023, a team of Rogel Cancer Center researchers landed one of these high-profile grants around a different theme. Their project centers around radiosensitization: how do specific drugs make radiation more effective in locally advanced pancreas, brain and breast cancers? Dr. Meredith Morgan, co-principle investigator explains.